Showing results (171-180 of 261) with videos related to
Sort By:
Pageof 27
International Journal of Radiation Oncology, Biology, Physics|February 18, 2014
Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivoLorenzo Agoni, Indranil Basu, Seema Gupta, et al.Cancer Research|November 17, 2005
Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesisHaritha K D L Reddy, Richard V Mettus, Sushil G Rane, et al.Molecular and Cellular Biology|July 1, 1989
Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin MN Malik, J C Kallestad, N L Gunderson, et al.The Journal of Experimental Medicine|April 1, 1994
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130X G Zhang, J J Gu, Z Y Lu, et al.Journal of Pharmaceutical and Biomedical Analysis|December 25, 2012
Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MSSool Yeon Cho, Stephen C Cosenza, Venkat Pallela, et al.Antiviral Research|July 30, 2013
A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesisLuis Martinez-Gil, Judith G Alamares-Sapuay, M V Ramana Reddy, et al.Journal of Immunogenetics|October 1, 1982
Mouse monoclonal anti-N. II. Physicochemical characterization and assessment for routine blood groupingR H Fraser, A C Munro, A R Williamson, et al.Journal of Immunogenetics|October 1, 1982
Mouse monoclonal anti-N. I. Production and serological characterizationR H Fraser, A C Munro, A R Williamson, et al.Journal of Immunogenetics|February 1, 1983
Monoclonal anti-B produced by the immunization of mice with soluble salivary glycoproteinsE K Barrie, R H Fraser, A C Munro, et al.Pharmaceutical Research|June 9, 2012
Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapySilpa Nuthalapati, Qingyu Zhou, Ping Guo, et al.Pageof 27